AvenCell Therapeutics to Present Phase 1a Results of CD123 CAR-T Therapy for AML
AvenCell Therapeutics is set to present the Phase 1a results of its switchable allogeneic CD123 CAR-T therapy, AVC-201, for acute myeloid leukemia (AML) at the European Hematology Association (EHA) Congress. The study, known as RevSTAR-123, evaluated AVC-201 in patients with CD123-positive relapsed/refractory or minimal residual disease positive AML. The therapy is designed to offer pharmacologic control through antigen-specific Target Modules, enabling off-the-shelf CAR-T cell therapy. The presentation will provide insights into the safety, tolerability, and efficacy of AVC-201, which has shown promise in preclinical studies. 
